Incremental Reduction in Risk of Death Associated With Use of Guideline‐Recommended Therapies in Patients With Heart Failure: A Nested Case‐Control Analysis of IMPROVE HF
Open Access
- 21 February 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 1 (1), 16-26
- https://doi.org/10.1161/jaha.111.000018
Abstract
Several therapies are guideline‐recommended to reduce mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction, but the incremental clinical effectiveness of these therapies has not been well studied. We aimed to evaluate the individual and incremental benefits of guideline‐recommended HF therapies associated with 24‐month survival. We performed a nested case‐control study of HF patients enrolled in IMPROVE HF. Cases were patients who died within 24 months and controls were patients who survived to 24 months, propensity‐matched 1:2 for multiple prognostic variables. Logistic regression was performed, and the attributable mortality risk from incomplete application of each evidence‐based therapy among eligible patients was calculated. A total of 1376 cases and 2752 matched controls were identified. β‐Blocker and cardiac resynchronization therapy were associated with the greatest 24‐month survival benefit (adjusted odds ratio for death 0.42, 95% confidence interval (CI), 0.34–0.52; and 0.44, 95% CI, 0.29–0.67, respectively). Angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, implantable cardioverter‐defibrillators, anticoagulation for atrial fibrillation, and HF education were also associated with benefit, whereas aldosterone antagonist use was not. Incremental benefits were observed with each successive therapy, plateauing once any 4 to 5 therapies were provided (adjusted odds ratio 0.31, 95% CI, 0.23–0.42 for 5 or more versus 0/1, P <0.0001). Individual, with a single exception, and incremental use of guideline‐recommended therapies was associated with survival benefit, with a potential plateau at 4 to 5 therapies. These data provide further rationale to implement guideline‐recommended HF therapies in the absence of contraindications to patients with HF and reduced left ventricular ejection fraction.Keywords
This publication has 23 references indexed in Scilit:
- The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart FailureArchives of Internal Medicine, 2011
- HFSA 2010 Comprehensive Heart Failure Practice GuidelineJournal of Cardiac Failure, 2010
- The American Heart Association’s Principles for Comparative Effectiveness ResearchCirculation, 2009
- 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Comparative effectiveness of angiotensin-converting-enzyme inhibitors: Is an ACE always an ace?CMAJ : Canadian Medical Association Journal, 2008
- ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the AdultCirculation, 2005
- The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart FailureJournal of the American College of Cardiology, 2005
- Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failureAmerican Heart Journal, 2003
- Clinical Research to Clinical Practice — Lost in Translation?The New England Journal of Medicine, 2003